Achieve Life Sciences (ACHV) Other Working Capital Changes (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Other Working Capital Changes of -$68000.0 in Q1 2026, down 105.07% on a QoQ basis from $1.3 million in Q4 2025, and up 20.0% year-over-year from -$56666.7 in Q1 2025.
Achieve Life Sciences (ACHV) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Other Working Capital Changes across 17 years of filings, most recently posting -$68000.0 for Q1 2026.
- Quarterly Other Working Capital Changes rose 20.0% year-over-year to -$68000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $413000.0 (up 127.37% YoY) and the FY2025 annual result came in at $322203.0, up 488086.36% from the prior year.
- Other Working Capital Changes declined to -$68000.0 in Q1 2026, from $1.3 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.3 million in Q4 2025 and troughed at -$886000.0 in Q1 2023.
- A 5-year average of -$46668.9 and a median of $25.0 in 2022 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes slumped 8960.0% — and 2025, when it surged 785760.98%.
- Tracing ACHV's Other Working Capital Changes over 5 years: stood at -$325000.0 in 2022, then plunged by 71.69% to -$558000.0 in 2023, then slumped by 38.71% to -$774000.0 in 2024, then jumped by 273.13% to $1.3 million in 2025, then sank by 105.07% to -$68000.0 in 2026.
- Business Quant data shows ACHV's Other Working Capital Changes at -$68000.0 in Q1 2026, $1.3 million in Q4 2025, and $322203.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68,000.00 |
| Mar 31, 2026 | -68,000.00 |
| Dec 31, 2025 | 1.34 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 322,203.00 |
| Sep 30, 2025 | 322,203.00 |
| Jun 30, 2025 | 322,203.00 |
| Jun 30, 2025 | 322,203.00 |
| Mar 31, 2025 | -85,000.00 |
| Mar 31, 2025 | -85,000.00 |
| Dec 31, 2024 | -774,000.00 |
| Dec 31, 2024 | -774,000.00 |
| Sep 30, 2024 | 66.00 |
| Sep 30, 2024 | 66.00 |
| Jun 30, 2024 | 41.00 |
| Jun 30, 2024 | 41.00 |
| Mar 31, 2024 | -92,000.00 |
| Mar 31, 2024 | -92,000.00 |
| Dec 31, 2023 | -558,000.00 |
| Dec 31, 2023 | -558,000.00 |